Pfizer whistleblower case heads to appeals court; Shire inks deal for rare kidney disease program;

Conversation on Twitter :

 @FierceBiotech: From FierceBiotechIT.com: Swedish bioinformatics group grabs $840K to fuel growth, report says. More | Follow @FierceBiotech

 @JohnCFierce: Signs of life? Top 10 biotech IPOs. Special Report | Follow @JohnCFierce

 @RyanMFierce: GSK's SROne leads $35M round for Thrasos Therapeutics for PhII study of kidney injury treatment. Release | Follow @RyanMFierce

> A federal appeals court is slated to hear Pfizer's ($PFE) argument that it should be let off the hook on a jury's award to whistleblower Becky McClain, a lab scientist who claimed that the company had retaliated against her after she claimed that she had become ill after being infected with a virus in the pharma giant's Groton, Connecticut, labs. Pfizer says it never interfered with her speech rights. OSHA found no violations in its inspection of the Groton facilities. Story

> Qiagen has struck a deal to collaborate with Bayer on new diagnostics, starting on drugs that target solid tumors. Report (reg. req.)

> In today's quarterly earnings report, Shire ($SHPG) notes that it struck a deal for a preclinical asset at IGAN Biosciences for IgA nephropathy, a rare kidney disease. Release

Pharma News

@FiercePharma: Novartis puts off restart at Lincoln, Neb., plant... again. Fed-up CEO says no more predictions--Bloomberg. News | Follow @FiercePharma

> What's AZ's new CEO thinking? Let's parse his words. Story

> Gilenya, Afinitor among bright spots in flat Novartis quarter. Article

> Novartis plant delay, vaccine woes steal spotlight. More

Medical Device News

 @FierceMedDev: Alere warned by FDA for cardio Dx quality shortfalls. Item | Follow @FierceMedDev

 @MarkHFierce: A Senate report blasts Medtronic for improperly shaping data regarding its Infuse bone graft, all to boost sales. Story | Follow @MarkHFierce

 @DamianFierce: 2012 was less than a banner year for med device and diagnostic IPOs. We take a look at the numbers: Report | Follow @DamianFierce

> J&J's Ethicon hit with Class I over stapler recall. News

> FDA chides St. Jude over CRM plant. Story

Vaccines News

@AlisonBFierce: U. of Texas at Austin researchers got $6.5M from Dept. of Defense to develop new vaccines for emerging health threats. More | Follow @AlisonBFierce

> Italy bans Novartis influenza vaccines. News

> CDC green-lights GSK's meningitis vaccine for at-risk infants. Item

> HIV antibody development discovery advances vaccine search. Story

> EMA: 'Insufficient' link between narcolepsy and GSK flu vaccine. Report

> Novavax reports positive avian flu vaccine results. Article

Pharma Manufacturing News

> DSM snags another project to feed Australian biologics plant. More

> Novartis CEO defends manufacturing lapses. Article

> FDA group argues for helping poor countries beef up oversight. Story

And Finally… Scientists are working on a new approach that could allow them to correct rare genetic diseases inherited in infants prior to conception. Story

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.